Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
AssigneeHadasit Medical Research Services and Development Ltd.
InventorsBernard Lerer, Lior Greenbaum
Life of this patent
Estimating the term…
Abstract
The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
Claims20
1-20. (canceled)
A method for assessing a tendency of a subject to develop extrapyramidal symptoms following treatment with an antipsychotic drug, which comprises:
- obtaining a sample comprising genetic material from the subject;
- determining, in the genetic material, the nucleotide sequence of the RGS2 gene or a fragment thereof;
- identifying in said nucleotide sequence at least one polymorphic site within said RGS2 gene or fragment thereof,
- wherein the identity of the at least one polymorphic site is indicative of the tendency to develop at least one extrapyramidal symptom following treatment with antipsychotic drugs.
Dependencies are inferred from the claim text.